| atezolizumab based treatment | durvalumab based treatment | pembrolizumab based treatment |
| atezolizumab plus carboplatin plus nab-paclitaxel | atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide | durvalumab alone | pembrolizumab alone |
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) | | | | |
es-BC - TNBC - NA - all population 5 | | | | |
es-BC - TNBC - NA - PDL1 positive 1 | | | | |